Physician profile
Sara E Henderson
NPI 1568055929
$3,553.59
in general payments reported to CMS, 2019-2025
27 companies · $916 in 2025
The $916 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $635 · 2023: $640 · 2024: $986 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,707.94 | 2021-2025 | Interstim, Altaviva |
| Sumitomo Pharma America, INC. | $376.54 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $299.52 | 2021-2023 | Urolift |
| Procept Biorobotics Corporation | $223.21 | 2023-2025 | Aquabeam Robotic System |
| Endo USA, INC. | $166.45 | 2024-2025 | Xiaflex, Aveed |
| Axonics, INC. | $112.43 | 2021-2023 | Axonics |
| Merck Sharp & Dohme LLC | $84.69 | 2024-2025 | Keytruda, Welireg |
| Antares Pharma, INC. | $83.90 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Biotech, INC. | $58.60 | 2024-2025 | Erleada |
| Abbvie INC. | $53.07 | 2022-2024 | |
| Urogen Pharma, INC. | $44.66 | 2025 | |
| Accord Healthcare, INC. | $40.71 | 2024 | |
| Urovant Sciences INC | $31.60 | 2022 | |
| Myriad Genetic Laboratories, INC. | $28.88 | 2024 | Prolaris |
| Astellas Pharma US INC | $24.60 | 2023 | Myrbetriq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $23.62 | 2023 | Xiaflex, Aveed |
| Alnylam Pharmaceuticals INC. | $22.62 | 2025 | Oxlumo |
| Tolmar, INC. | $20.09 | 2024 | |
| Boston Scientific Corporation | $20.06 | 2023 | Rezum Generator |
| Sun Pharmaceutical Industries INC. | $19.31 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.78 | 2023 | |
| Blue Earth Diagnostics | $17.27 | 2021 | |
| Myovant Sciences INC. | $15.65 | 2022 | |
| Pfizer INC. | $14.09 | 2022 | |
| Immunitybio, INC. | $13.70 | 2024 | |
| Halozyme INC | $13.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.